Michael P. Manos

5.6k total citations · 1 hit paper
39 papers, 1.3k citations indexed

About

Michael P. Manos is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Michael P. Manos has authored 39 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 14 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in Michael P. Manos's work include Cancer Immunotherapy and Biomarkers (25 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Michael P. Manos is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (8 papers). Michael P. Manos collaborates with scholars based in United States, Canada and United Kingdom. Michael P. Manos's co-authors include F. Stephen Hodi, Anita Giobbie‐Hurder, Jun Zhou, Mariano Severgnini, Lauren M. Eastman, Osama E. Rahma, Scott J. Rodig, Xiaoyun Liao, Xinqi Wu and Mizuki Nishino and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Michael P. Manos

34 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

2020 307 citations Adrienne Luoma, Shengbao Suo et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael P. Manos United States	13	933	572	315	224	128	39	1.3k
Jasmine I. Rizzo United States	8	1.1k 1.2×	465 0.8×	382 1.2×	239 1.1×	91 0.7×	18	1.3k
Miren Zuazo Spain	17	1.0k 1.1×	760 1.3×	296 0.9×	195 0.9×	123 1.0×	27	1.4k
Justin D. Saco United States	4	966 1.0×	792 1.4×	368 1.2×	216 1.0×	142 1.1×	5	1.4k
Jingwei Sun China	11	717 0.8×	753 1.3×	438 1.4×	193 0.9×	109 0.9×	22	1.3k
Tuba N. Gide Australia	12	1.3k 1.4×	985 1.7×	385 1.2×	240 1.1×	147 1.1×	22	1.7k
Aixa Soyano United States	9	713 0.8×	482 0.8×	234 0.7×	229 1.0×	110 0.9×	30	1.1k
Lucia Festino Italy	18	880 0.9×	375 0.7×	368 1.2×	190 0.8×	109 0.9×	39	1.2k
Maria Libera Ascierto United States	19	677 0.7×	577 1.0×	397 1.3×	188 0.8×	181 1.4×	44	1.2k
Mevyn Nizard France	5	729 0.8×	500 0.9×	270 0.9×	234 1.0×	169 1.3×	5	1.1k
Diwakar Davar United States	20	1.1k 1.2×	810 1.4×	490 1.6×	183 0.8×	105 0.8×	134	1.6k

Countries citing papers authored by Michael P. Manos

Since Specialization

Citations

This map shows the geographic impact of Michael P. Manos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Manos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Manos more than expected).

Fields of papers citing papers by Michael P. Manos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Manos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Manos. The network helps show where Michael P. Manos may publish in the future.

Co-authorship network of co-authors of Michael P. Manos

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Manos. A scholar is included among the top collaborators of Michael P. Manos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Manos. Michael P. Manos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hodi, F. Stephen, Anita Giobbie‐Hurder, Kwasi Adu‐Berchie, et al.. (2025). First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma. Cancer Immunology Research. 13(7). 978–989. 5 indexed citations

Khaddour, Karam, Rizwan Haq, Elizabeth I. Buchbinder, et al.. (2024). Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma. The Oncologist. 30(3).

Manos, Michael P., et al.. (2024). Abstract 2750: Leveraging machine-learning approaches to dissect drivers of clinical metastatic dynamics in lung adenocarcinoma. Cancer Research. 84(6_Supplement). 2750–2750.

Tabasum, Saba, Dinesh Thapa, Anita Giobbie‐Hurder, et al.. (2023). EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade. Cancer Immunology Research. 11(11). 1493–1507. 13 indexed citations

Lindsay, James, Bijaya Sharma, Kristen D. Felt, et al.. (2023). Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. Cancer Research. 83(7_Supplement). 5706–5706. 1 indexed citations

Buchbinder, Elizabeth I., Sandra J. Lee, Kimberly W. Keefe, et al.. (2023). Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.. Journal of Clinical Oncology. 41(16_suppl). 12013–12013. 8 indexed citations

Wei, Alexander Z., Michael P. Manos, Jasmine H. Francis, et al.. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology. 12. 961517–961517. 6 indexed citations

Giobbie‐Hurder, Anita, Isaac A. Klein, Michael P. Manos, et al.. (2021). Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. SHILAP Revista de lepidopterología. 4(2). 35–44. 8 indexed citations

Miller, Peter G., Adam S. Sperling, Christopher J. Gibson, et al.. (2020). A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 106(2). 651–654. 3 indexed citations

10.

Luoma, Adrienne, Shengbao Suo, Hannah L. Williams, et al.. (2020). Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 182(3). 655–671.e22. 307 indexed citations breakdown →

11.

Zhou, Jun, Jingjing Li, Indira Guleria, et al.. (2019). Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. Cancer Immunology Immunotherapy. 68(8). 1331–1340. 3 indexed citations

12.

Montero, Joan, Cécile Gstalder, Daniel J. Kim, et al.. (2019). Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications. 10(1). 5157–5157. 42 indexed citations

13.

Schoenfeld, Jonathan D., Mizuki Nishino, Mariano Severgnini, et al.. (2019). Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. Journal for ImmunoTherapy of Cancer. 7(1). 112–112. 64 indexed citations

14.

Miller, Brian C., Debattama R. Sen, Rose Al Abosy, et al.. (2019). Abstract 2701: Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade. Cancer Research. 79(13_Supplement). 2701–2701. 3 indexed citations

15.

Nguyen, Ngan, Mariano Severgnini, Xinqi Wu, et al.. (2018). Abstract 615: Increased somatic hypermutation in the immunoglobulin sequences of melanoma patients who have durable response to checkpoint inhibitor therapy. Cancer Research. 78(13_Supplement). 615–615. 3 indexed citations

16.

Subrahmanyam, Priyanka B., Zhiwan Dong, Daniel Gusenleitner, et al.. (2018). Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. Journal for ImmunoTherapy of Cancer. 6(1). 18–18. 137 indexed citations

17.

Zhou, Jun, Kathleen M. Mahoney, Anita Giobbie‐Hurder, et al.. (2017). Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research. 5(6). 480–492. 284 indexed citations

18.

Nishino, Mizuki, Anita Giobbie‐Hurder, Michael P. Manos, et al.. (2017). Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research. 23(16). 4671–4679. 95 indexed citations

19.

Wu, Xinqi, Anita Giobbie‐Hurder, Xiaoyun Liao, et al.. (2016). Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research. 5(1). 17–28. 123 indexed citations

20.

Liu, Jie, et al.. (2008). Project Genome: Wireless Sensor Network for Data Center Cooling. 82(2). 315–324. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact